<i>In vitro</i> exploration of drug-induced thrombotic microangiopathies: clues of diverse endothelial activation pathways respective to interferon-β1a, ciclosporin A, and gemcitabine exposure. [PDF]
Cubilier E +6 more
europepmc +1 more source
Educational Case: Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies and Potential Role of the Spleen. [PDF]
Nichols MM, Crane GM.
europepmc +1 more source
The impact of the COVID-19 pandemic on incidence and clinical presentation of thrombotic microangiopathies: data from a laboratory centralizing ADAMTS-13 testing in Quebec. [PDF]
Merlen C +8 more
europepmc +1 more source
Toward a Restrictive Use of Plasma Exchanges in Thrombotic Microangiopathies. [PDF]
Frimat M +3 more
europepmc +1 more source
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. [PDF]
Ahmad +65 more
core +1 more source
The Interaction Between Coagulation and Complement Cascades in the Management of Thrombotic Microangiopathies Related to Postpartum Hemorrhage. [PDF]
Orsi M, Ossola MW, Cetin I, Ardissino G.
europepmc +1 more source
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients [PDF]
core +1 more source
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies
S. Olson +5 more
semanticscholar +1 more source

